Medical Device

Obalon Therapeutics (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its audited financial results as of and for the fourth quarter and full year ended December 31, 2017. As quoted in the press release: Q4-17 total revenue of $3.7 …

Obalon Therapeutics (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its audited financial results as of and for the fourth quarter and full year ended December 31, 2017.

As quoted in the press release:

  • Q4-17 total revenue of $3.7 million grew 32% sequentially over Q3-17
  • Q4-17 U.S. revenue of $2.9 million grew 43% sequentially over Q3-17
  • Highest number of new U.S. accounts sold of any quarter since U.S. launch
  • U.S. reorder revenue exceeds revenue from new account additions for first quarter since U.S. launch
  • Gross margin improved to 54%

Click here to read the full press release.

MARKETS

Markets
TSX19062.91+345.79
TSXV647.33+15.54
DOW31500.68+823.32
S&P 5003911.74+116.01
NASD11607.62+375.43
ASX6528.40+19.90

COMMODITIES

Commodities
Gold1827.54+0.47
Silver21.15+0.03
Copper3.740.00
Palladium1879.51+6.50
Platinum911.26+4.32
Oil107.06+2.79
Heating Oil4.24+0.02
Natural Gas6.17-0.07

DOWNLOAD FREE REPORTS

×